A type of coronavirus, NeoCov, that spreads among bats in South Africa may pose a threat to humans in future if it mutates further, according to a study by Chinese researchers.
The yet-to-be peer-reviewed study recently posted on the preprint repository BioRxiv, shows that NeoCov is closely related to the Middle East respiratory syndrome (MERS), a viral disease first identified in Saudi Arabia in 2012.
Coronaviruses are a large family of viruses that can cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS).
Researchers from Chinese Academy of Sciences and Wuhan University noted that NeoCov is found in a population of bats in South Africa and to date spreads exclusively among these animals.
In its current form, NeoCov does not infect humans but further mutations may make it potentially harmful, the researchers noted.
"In this study, we unexpectedly found that NeoCoV and its close relative, PDF-2180-CoV, can efficiently use some types of bat Angiotensin-converting enzyme 2 (ACE2) and, less favourably, human ACE2 for entry," the authors of the study noted.
ACE2 is a receptor protein on cells that provides the entry point for the coronavirus to hook into and infect a wide range of cells.
"Our study demonstrates the first case of ACE2 usage in MERS-related viruses, shedding light on a potential bio-safety threat of the human emergence of an ACE2 using "MERS-CoV-2" with both high fatality and transmission rate," they said.
The researchers further noted that infection with NeoCov could not be cross-neutralised by antibodies targeting SARS-CoV-2 or MERS-CoV.
"Considering the extensive mutations in the RBD regions of the SARS-CoV-2 variants, especially the heavily mutated Omicron variant, these viruses may hold a latent potential to infect humans through further adaptation," the authors of the study added.
A receptor-binding domain (RBD) is a key part of a virus that allows it to dock to body receptors to gain entry into cells and lead to infection.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU